A Multicenter Evaluation of the Time-Course of Action of Two Doses of Rapacuronium After Early and Late Reversal with Neostigmine

Early reversal of rapacuronium may accelerate return of neuromuscular function. This study was designed to compare early (2 min after rapacuronium) or late (at 25% recovery of the first twitch [T1] of train-of-four) reversal of rapacuronium with neostigmine. We studied 119 subjects between the ages of 18 and 75 yr. Anesthesia was induced with fentanyl and thiopental and maintained with nitrous oxide, propofol, and fentanyl. Mechanomyographic neuromuscular monitoring was performed by using train-of-four stimulation of the ulnar nerve. Two groups received 1.5 mg/kg rapacuronium followed by neostigmine (50 &mgr;g/kg) and glycopyrrolate (10 &mgr;g/kg) either at 2 min after rapacuronium bolus or at 25% T1 recovery. The other two groups received 2.0 mg/kg rapacuronium, after which neostigmine was similarly given. For each rapacuronium dose, the time from the administration of rapacuronium to the start of T1 recovery or 25% T1 recovery was significantly shorter in subjects who received the reversal 2 min after rapacuronium. However, late recovery, defined by times from administration of rapacuronium to 70%, or 80% T4/T1 recovery, was not influenced by early reversal administration. We conclude that initial recovery is accelerated by early administration of neostigmine. Time to full recovery after rapacuronium administration is, however, dose-dependent and not significantly altered by early administration of neostigmine.

[1]  M. Goldberg,et al.  Clinical Pharmacology of Rapacuronium Bromide, a New Short‐Acting Neuromuscular Blocking Agent , 1999, Pharmacotherapy.

[2]  D. Bevan,et al.  Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. , 1999, Anesthesia and analgesia.

[3]  F. Donati,et al.  Early reversal of rapacuronium with neostigmine. , 1999, Anesthesiology.

[4]  D. Fisher,et al.  A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. , 1999, Anesthesiology.

[5]  J. Proost,et al.  Comparison of vecuronium with ORG 9487 and their interaction , 1997, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[6]  R. Matteo,et al.  Dose-Ranging Study in Younger Adult and Elderly Patients of ORG 9487, a New, Rapid-Onset, Short-Duration Muscle Relaxant , 1997, Anesthesia and analgesia.

[7]  P. Lindholm,et al.  Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade , 1996, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[8]  L. Skovgaard,et al.  Good Clinical Research Practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents , 1996, Acta anaesthesiologica Scandinavica.

[9]  J. Proost,et al.  Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. , 1994, British journal of anaesthesia.

[10]  J. Wierda,et al.  Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487 , 1994, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[11]  K.,et al.  Time Course of Action and Endotracheal Intubating Conditions of Org 9487, a New Short‐Acting Steroidal Muscle Relaxant; A Comparison with Succinylcholine , 1993, Anesthesia and analgesia.

[12]  R. Miller,et al.  Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? , 1990, Anesthesiology.